Interview with Greg B. Scott, President & Founder, ChinaBio® LLC
This is our first meeting in Shanghai after being based in Beijing for two months – what if any are the differences between the two cities? At the top level,…
Address: ChinaBio® LLC Biotech VC Plaza Zhangjiang Hi-Tech Park 780 Cailun Road, Suite 822 Pudong New Area, Shanghai P.R. China 201203 ,China
Tel: -5823
Web: http://www.chinabiollc.com/
Since its founding in January, 2007, ChinaBio® LLC has rapidly launched a number of initiatives accelerating the globalization of China’s life science industry. ChinaBio has helped China companies raise nearly $500 million and global life science companies identify over 400 licensing and acquisition opportunities in China.
• Conferences: ChinaBio organizes the premier life science investment and partnering conferences in China, having attracted over 4,000 attendees. • Consulting: ChinaBio works with global life science companies and China entrepreneurs to define and execute a successful global strategy. • Transactions: ChinaBio helps companies secure partnerships and acquisitions and access private and government funding in China. • Publishing: ChinaBio® Today is the most widely read online and email newsletter on China’s life science industry.
This is our first meeting in Shanghai after being based in Beijing for two months – what if any are the differences between the two cities? At the top level,…
Writing in the February edition of DIA’s Global Forum magazine, Xu Wang of Novo Nordisk Pharma China and Xiaoxi Wang from the Shanghai Center for Drug Evaluation & Inspection analyse…
Dr Liang Schweizer introduces immunotherapy-focused biotech HiFiBiO Therapeutics, the main advantages of the company’s unique single-cell technology platform, its open innovation approach, experience with capital markets, and advice for other…
Eric Bouteiller examines the most recent update to China’s National Reimbursement Drug List, the positive impact that a de facto annual review has had on drug approval timelines, and why…
Since China first announced its ground-breaking volume-based procurement (VBP) pilot program to reduce drug expenditures in 2018, the world’s second-largest pharma market has steadily expanded the 4+7 pilot program into…
2020 has been eventful – perhaps the understatement of the year – but despite the novel coronavirus being discovered in China around the beginning of 2020, the country bounced back…
Following the recent news of Remegen’s massive USD 515 million IPO in November 2020, we bring you profiles of the seven biggest biotech companies to IPO in 2020. Notably, six…
The latest from Chinese pharma, including domestic regulatory approval for Sinopharm’s COVID-19 vaccine, how the country’s online healthcare industry is booming in the wake of the pandemic, and news that…
The latest from Chinese pharma, including a drop in share prices for Chinese vaccine firms in the wake of successful COVID-19 trial results from western rivals, a new Pfizer-LianBio agreement,…
PharmaBoardroom had the pleasure of interviewing HitGen chairman & CEO Dr Jin LI in July regarding the company’s focus on DNA-encoded chemical libraries (DEL) and their multipronged business strategy. Established…
RemeGen, a low-profile Chinese biotech company based in Yantai city in the coastal Shandong province, around nine hours by train from the bustling biopharma hub of Shanghai, just made history…
A roundup of the latest from Chinese pharma, including Green Valley’s upcoming US trial for an Alzheimer’s drug inspired by algae; Samsung Biologics expansion in China; Fosun Pharma’s halt to…
While cell and gene therapies are all the rage now, a little known fact is that the world’s first approved gene therapy actually came from a Chinese company – in…
See our Cookie Privacy Policy Here
